Saved in this browser. Sign in to sync across devices.
Status check: Obuprazine (HS-10380, also called TRTL-107) is investigational. It is not FDA-approved or an option for routine prescribing in the United States. No one should stop, replace or adjust prescribed antipsychotics because of this announcement.
What was announced?
On October 12, 2026, Hansoh Pharma described results presented at the European College of Neuropsychopharmacology meeting on October 10. The company studied obuprazine, an oral drug candidate acting on several dopamine and serotonin receptors, in adults with acute schizophrenia in China.
STUDY DESIGN
363 participants
Randomized across three obuprazine dose ranges, aripiprazole as an active comparison group, and placebo. The controlled study assessed short-term outcomes.
PRIMARY SYMPTOM MEASURE
42 days
The Positive and Negative Syndrome Scale (PANSS) measures schizophrenia symptom severity. A lower score indicates improvement.
EFFICACY SIGNAL
All three doses
Each studied obuprazine range showed a larger reduction in PANSS total scores than placebo after 42 days.
WHAT IS STILL MISSING
Long-term evidence
Independent peer review, larger confirmatory studies, durable functioning outcomes and a fuller safety picture are still needed.
How large was the reported symptom change?
The company reported placebo-adjusted, least-squares-mean PANSS differences at day 42 of −16.7 points for the 1.5–3 mg group, −13.2 for the 4.5–6 mg group and −14.7 for the 6–9 mg group. The aripiprazole reference group had a reported difference of −12.1 points. These are comparisons with placebo, not proof that obuprazine outperforms aripiprazole or other approved medicines.
Hansoh also described favorable patterns on measures of positive symptoms, negative symptoms and a PANSS cognitive-factor score. A cognitive-factor score is not the same as proving a clinically meaningful improvement in cognition or everyday independence.
What about side effects?
The sponsor described treatment-emergent adverse events as mostly mild or moderate and said no new major short-term safety concern was identified. That is a company-reported, 42-day finding. It cannot answer questions about long-term metabolic effects, movement disorders, rare reactions, maintenance treatment, or people with several overlapping conditions.
What happens next?
- Publication: Investigators submit the full protocol, statistical analysis and safety data for independent peer review.
- Confirmation: Larger and longer studies examine whether the benefit is reproducible, clinically meaningful and acceptably safe.
- Regulatory review: Authorities assess a specific indication. A successful early trial does not guarantee authorization.
Questions families can ask now
- Which symptoms and functioning goals are hardest to manage with current treatment?
- What established options, psychosocial supports and medication-monitoring approaches are appropriate today?
- If considering a future clinical trial, what are the eligibility requirements, risks, oversight and alternatives?
Keep established care in view
Current antipsychotic treatment and personalized psychiatric follow-up remain central to managing schizophrenia. A study in acute illness does not establish a treatment for chronic negative symptoms or treatment-resistant schizophrenia.
Original sources and verification
- Hansoh Pharma — October 12, 2026 Phase 2b results and ECNP poster details ↗
Primary sponsor report; not yet a peer-reviewed journal article
- ClinicalTrials.gov — official clinical study registry ↗
Verify any future study's registration, eligibility and recruiting status with the official registry
Evidence checked October 13, 2026 · Educational editorial draft; independent clinical review pending. Regulatory and recruiting statuses can change.